Appendix

Susceptibility Testing: Patient 1

Bacterium	Antibiotic	Sensitivity	MIC
Pseudomonas aeruginosa			
	Amikacin	S	–
	Aztreonam	S	–
	Cefepime	S	–
	Ceftazidime	S	–
	Ciprofloxacin	S	–
	Gentamicin	S	–
	Imipenem	S	–
	Meropenem	S	–
	Piperacillin/Tazobactam	S	–
Staphylococcus aureus			
	Cefazolin	S	–
	Diprofloxacin	S	≤0.5
	Clindamycin	S	≤0.25
	Daptomycin	S	0.5
	Erythromycin	R	≥8
	Gentamicin	S	≤0.5
	Levofloxacin	S	0.25
	Linezolid	S	2

	Oxacillin	S	0.5
	Rifampin	S	≤0.5
	Tetracycline	S	≤1
	Tigecycline	S	≤0.12
	Trimethoprim/Sulfametoxazole	S	≤10
	Vancomycin	S	1
Enterobacter cloacae			
	Amikacin	S	
	Aztreonam	S	
	Cefazolin	R	
	Cefepime	S	
	Ceftriaxone	S	
	Ertapenem	S	
	Gentamicin	S	
	Levofloxacin	S	
	Meropenem	S	
	Piperacillin/Tazobactam	S	
	Tetracycline	S	
	Tigecycline	S	
	Trimethoprim/Sulfamethoxazole	S	

MIC, minimum inhibitory concentration in μg/mL; S, sensitive; R, resistant.

Susceptibility Testing: Patient 2

Bacterium	**Antibiotic**	**Sensitivity**	**MIC**
Pseudomonas aeruginosa			
	Amikacin	S	–
	Aztreonam	S	–
	Cefepime	S	–
	Ceftazidime	S	–
	Ciprofloxacin	S	–
	Gentamicin	I	–
	Imipenem	S	–
	Meropenem	S	–
	Piperacillin/Tazobactam	S	–
Coagulase-negative *Staphylococcus*, not *S. lugdunensis*			
	Ciprofloxacin	R	≥8
	Clindamycin	R	≥8
	Daptomycin	S	0.5
	Erythromycin	R	≥8
	Gentamicin	R	≥16
	Levofloxacin	R	≥8
	Linezolid	S	1
	Oxacillin	R	≥4

Rifampin	S	≤0.5
Tetracycline	R	≥16
Tigecycline	S	0.25
Trimethoprim/Sulfametoxazole	R	160
Vancomycin	S	1

MIC, minimum inhibitory concentration in μg/mL; S, sensitive; I, intermediate; R, resistant.

Susceptibility Testing: Patient 3

Bacterium	Antibiotic	Sensitivity	MIC
Enterococcus spp.			
	Ampicillin	R	≥32
	Erythromycin	R	≥8
	Gentamicin, high level	SNL*	–
	Streptomycin, high level	SNL*	–
	Vancomycin	S	–
Escherichia coli			
	Amikacin	S	≤2
	Ampicillin/Sulbactam	S	≤2
	Aztreonam	S	≤1
	Cefazolin	S	≤4
	Cefepime	S	≤1
	Ceftriaxone	S	≤1
	Ertapenem	S	≤0.5
	Gentamicin	S	≤1
	Levofloxacin	S	≤0.12
	Meropenem	S	≤0.25
	Piperacillin/Tazobactam	S	≤4
	Tetracycline	S	≤1
	Tigecycline	S	≤0.5

	Trimethoprim/Sulfametoxazole	S	≤20
Klebsiella pneumonia spp.			
	Amikacin	S	≤2
	Ampicillin/Sulbactam	S	≤2
	Aztreonam	S	≤1
	Cefazolin	S	≤4
	Cefepime	S	≤1
	Ceftriaxone	S	≤1
	Ertapenem	S	≤0.5
	Gentamicin	S	≤1
	Levofloxacin	S	≤0.12
	Meropenem	S	≤0.25
	Piperacillin/Tazobactam	S	≤4
	Tetracycline	S	≤1
	Tigecycline	S	≤0.5
	Trimethoprim/Sulfametoxazole	S	≤20

MIC, minimum inhibitory concentration in μg/mL; R, resistant; SNL, synergy not likely; S, sensitive.

*In vitro testing indicates likely failure of synergy with ampicillin.

Susceptibility Testing: Patient 4	
Bacterium	
Corynebacterium	Light Growth *Corynebacterium* species, not *jeikeium* Reproducible definitive standards to interpret susceptibility results are not yet available for *Corynebacterium* and *Bacillus* species. The microbiology laboratory at our center does not perform susceptibility testing on these organisms.

Susceptibility Testing: Patient 5

Bacterium	**Antibiotic**	**Sensitivity**	**MIC**
Enterococcus spp.			
	Ampicillin	S	≤2
	Erythromycin	R	≥8
	Gentamicin, high level	SNL*	–
	Linezolid	S	2
	Streptomycin, high level	SNL*	–
	Tigecycline	S	≤0.12
	Vancomycin	S	1

MIC, minimum inhibitory concentration in μg/mL; S, sensitive; R, resistant; SNL, synergy not likely; MIC, minimum inhibitory concentration in μg/mL.

*In vitro testing indicates likely failure of synergy with ampicillin.

Susceptibility Testing: Patient 6

Bacterium	Antibiotic	Sensitivity	MIC
Enterobacter gergoviae			
	Amikacin	S	16
	Aztreonam	R	16
	Cefazolin	R	≥64
	Cefepime	S	≤1
	Ceftazidime	R	≥64
	Colistin	S	–
	Ertapenem	S	≤0.5
	Gentamicin	S	≤1
	Levofloxacin	S	0.5
	Meropenem	S	≤0.25
	Piperacillin/Tazobactam	S	≤4
	Tetracycline	S	≤1
	Tigecycline	S	≤0.5
	Trimethoprim/Sulfamethoxazole	R	≥320
Coagulase-negative *Staphylococcus*, not *S. lugdunensis*			
	Cefazolin	S	–
	Ciprofloxacin	S	≤0.5
	Clindamycin	S	≤0.25

Daptomycin	S	0.25
Erythromycin	R	≥8
Gentamicin	S	≤0.5
Levofloxacin	S	≤0.12
Linezolid	S	2
Oxacillin	S	≤0.25
Rifampin	S	≤0.5
Tetracycline	S	≥1
Tigecycline	S	≤0.12
Trimethoprim/Sulfametoxazole	S	≤10
Vancomycin	S	≤0.5

MIC, minimum inhibitory concentration in μg/mL; S, sensitive; R, resistant.

Susceptibility Testing: Patient 7

Bacterium	Antibiotic	Sensitivity	MIC
Enterococcus spp.			
	Ampicillin	R	≥32
	Erythromycin	R	≥8
	Gentamicin, high level	SNL*	–
	Linezolid	S	2
	Streptomycin, high level	SNL*	–
	Tigecycline	S	≤0.12
	Vancomycin	R	≥32
Escherichia coli			
	Amikacin	S	≤2
	Ampicillin/Sulbactam	R	≥32
	Aztreonam	S	≤1
	Cefazolin	R	≥64
	Cefepime	S	≤1
	Ceftriaxone	S	≤1
	Ertapenem	S	≤0.5
	Gentamicin	S	≤1
	Levofloxacin	R	≥8
	Meropenem	S	≤0.25
	Piperacillin/Tazobactam	R	≥128

Tetracycline	R	≥16
Tigecycline	S	≤0.5
Trimethoprim/Sulfametoxazole	S	≤20

MIC, minimum inhibitory concentration in μg/mL; R, resistant; SNL, synergy not likely; S, sensitive.

*In vitro testing indicates likely failure of synergy with ampicillin.

Susceptibility Testing: Patient 8

Bacterium	Antibiotic	Sensitivity	MIC
Enterobacter cloacae complex			
	Amikacin	S	≤2
	Aztreonam	S	≤1
	Cefazolin	R	≥64
	Cefepime	S	≤1
	Ceftriaxone	S	≤1
	Ertapenem	S	≤0.5
	Gentamicin	S	≤1
	Levofloxacin	S	≤0.12
	Meropenem	S	≤0.25
	Piperacillin/Tazobactam	S	≤4
	Tetracycline	S	≤1
	Tigecycline	S	1
	Trimethoprim/Sulfametoxazole	S	≤20
Serratia marcescens			
	Amikacin	S	≤2
	Aztreonam	S	≤1
	Cefazolin	R	≥64
	Cefepime	S	≤1
	Ceftriaxone	S	≤1

Ertapenem	S	≤0.5
Gentamicin	S	≤1
Levofloxacin	S	≤0.12
Meropenem	S	≤0.25
Piperacillin/Tazobactam	S	
Tetracycline	R	≥16
Tigecycline	S	2
Trimethoprim/Sulfametoxazole	S	≤20

MIC, minimum inhibitory concentration in μg/mL; S, sensitive; R, resistant.

Susceptibility Testing: Patient 9

Bacterium	Antibiotic	Sensitivity	MIC
Coagulase-negative *Staphylococcus*, not *S. lugdunensis*			
	Ampicillin	R	–
	Cefazolin	R*	–
	Ciprofloxacin	R*	≥8
	Clindamycin	R	≥4
	Daptomycin	S	0.5
	Doxycycline	S	1
	Erythromycin	R	≥8
	Gentamicin	S	≤0.5
	Levofloxacin	R	≥8
	Linezolid	S	2
	Oxacillin	R	≥4
	Rifampin	S	≤0.5
	Tetracycline	S	4
	Tigecycline	S	0.25
	Trimethoprim/Sulfametoxazole	R	160
	Vancomycin	S	2

MIC, minimum inhibitory concentration in μg/mL; R, resistant; S, sensitive.

*Resistant to cephalosporins.

Susceptibility Testing: Patient 10

Bacterium	Antibiotic	Sensitivity	MIC
Enterococcus spp.			
	Ampicillin	R	≥32
	Daptomycin	S	4
	Doxycycline	S	4
	Erythromycin	R	≥8
	Gentamicin, high level	SNL*	–
	Linezolid	S	2
	Streptomycin, high level	SNL*	–
	Tigecycline	S	≤0.12
	Vancomycin	R	≥32
Klebsiella pneumonia spp.			
	Amikacin	S	≤2
	Ampicillin/Sulbactam	R	≥32
	Aztreonam	R	16
	Cefazolin	R	≥64
	Cefepime	I	2
	Ceftriaxone	R	≥64
	Ertapenem	S	≤0.5
	Gentamicin	S	≤1
	Levofloxacin	R	≥8

	Meropenem	S	≤0.25
	Piperacillin/Tazobactam	S	16
	Tetracycline	R	≥16
	Trimethoprim/Sulfametoxazole	R	≥320
Morganella morganii spp.			
	Amikacin	S	≤2
	Ampicillin/Sulbactam	R	≥32
	Aztreonam	S	≤1
	Cefazolin	R	≥64
	Cefepime	S	≤1
	Ceftriaxone	I	2
	Ertapenem	S	≤0.5
	Gentamicin	R	≥16
	Levofloxacin	R	≥8
	Meropenem	S	≤0.25
	Piperacillin/Tazobactam	S	≤4
	Tetracycline	R	≥16
	Trimethoprim/Sulfametoxazole	R	≥320
Proteus mirabilis			
	Amikacin	S	8
	Ampicillin/Sulbactam	R	≥32
	Aztreonam	S	≤1

Cefazolin	R	≥64
Cefepime	R	≥64
Ceftriaxone	R	16
Ertapenem	I	1
Gentamicin	I	8
Levofloxacin	I	4
Meropenem	S	1
Piperacillin/Tazobactam	S	16
Tetracycline	R	≥16
Trimethoprim/Sulfametoxazole	R	≥320

MIC, minimum inhibitory concentration in μg/mL; R, resistant; S, sensitive; SNL, synergy not likely; I, intermediate.

*In vitro testing indicates likely failure of synergy with ampicillin.